These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

80 related items for PubMed ID: 10560396

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Treatment of peritoneal carcinomatosis using carboplatin-loaded hydroxyapatite particles.
    Takeyama H, Mohri N, Mizuno I, Akamo Y, Sawai H, Manabe T, Yotsuyanagi T, Nakamura S.
    Anticancer Res; 2006; 26(6B):4603-6. PubMed ID: 17201184
    [Abstract] [Full Text] [Related]

  • 3. [Antitumor effects of liposome-entrapped carboplatin (Lipo-CBDCA) after intraperitoneal administration in rats bearing carcinomatous peritonitis].
    Mizuno I, Yasui T, Takeyama H, Ishikawa M, Terada J, Mohri N, Ueda T, Sumita N, Kobayashi K, Akamo Y.
    Gan To Kagaku Ryoho; 1995 Sep; 22(11):1598-601. PubMed ID: 7574769
    [Abstract] [Full Text] [Related]

  • 4. [Intraperitoneal administration of carboplatin loaded alpha-tricalcium phosphate (alpha-TCP) particles in rats bearing abdominal carcinomatosis].
    Ueda T, Mizuno I, Mohri N, Akamo Y, Terada J, Shibata T, Yamamoto T, Takeyama H, Manabe T, Yotsuyanagi T.
    Gan To Kagaku Ryoho; 1996 Sep; 23(11):1512-5. PubMed ID: 8854793
    [Abstract] [Full Text] [Related]

  • 5. [The pharmacokinetics of intraperitoneal (IP) carboplatin (CBDCA) and dose-up study of intravenous (IV) cyclophosphamide (CPM) in combination with IP CBCDA for advanced ovarian cancer patients].
    Fujiwara K, Yamauchi H, Sawada S, Koike H, Mohri H, Ohishi Y, Kohno I.
    Gan To Kagaku Ryoho; 1992 Dec; 19(14):2373-9. PubMed ID: 1463344
    [Abstract] [Full Text] [Related]

  • 6. [Antitumor effect of liposome-entrapped carboplatin after intraperitoneal administration in rats].
    Yasui T, Mizuno I, Ichino T, Akamo Y, Yamamoto T, Itabashi Y, Saito T, Kurahashi S, Tanimoto N, Yura J.
    Gan To Kagaku Ryoho; 1992 Aug; 19(10 Suppl):1753-5. PubMed ID: 1530349
    [Abstract] [Full Text] [Related]

  • 7. [Clinical pharmacokinetics of carboplatin and MCNU in malignant brain tumor and normal brain tissues].
    Shinohara C, Matsumoto K, Kuriyama M, Adachi H, Ono Y, Higashi H, Furuta T, Ohmoto T.
    Gan To Kagaku Ryoho; 1994 Jul; 21(8):1163-8. PubMed ID: 8031157
    [Abstract] [Full Text] [Related]

  • 8. A Bayesian dosing method for carboplatin given by continuous infusion for 120 h.
    Guillet P, Monjanel S, Nicoara A, Duffaud F, Lacarelle B, Bagarry-Liegey D, Durand A, Catalin J, Favre R.
    Cancer Chemother Pharmacol; 1997 Jul; 40(2):143-9. PubMed ID: 9182836
    [Abstract] [Full Text] [Related]

  • 9. Combination treatment of cis- and carboplatin in cancers restricted to the peritoneal cavity in the rat.
    Los G, Tuyt L, van Vugt M, Schornagel J, Pinedo HM.
    Cancer Chemother Pharmacol; 1993 Jul; 32(6):425-33. PubMed ID: 8258189
    [Abstract] [Full Text] [Related]

  • 10. [Pharmacokinetics of carboplatin after intraperitoneal administration and clinical effect in ovarian cancer].
    Ohno M, Hirokawa M, Hando T.
    Gan To Kagaku Ryoho; 1992 Dec; 19(14):2355-61. PubMed ID: 1463342
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Vasopressin modulation of peritoneal, lymphatic, and plasma drug exposure following intraperitoneal administration.
    Lindnér P, Heath D, Howell S, Naredi P, Hafström L.
    Clin Cancer Res; 1996 Feb; 2(2):311-7. PubMed ID: 9816174
    [Abstract] [Full Text] [Related]

  • 13. [Comparison of pelvic transarterial chemoembolization with lipiodol ultra-fluid carboplatin and transarterial carboplatin through experiment in dogs].
    Chen CL, Sun MH, Tan DC, Liang LZ.
    Ai Zheng; 2004 Nov; 23(11 Suppl):1405-8. PubMed ID: 15566645
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Carboplatin AUC and gamma-glutamylcysteine synthetase gene expression in peripheral mononuclear cells of lung cancer patients.
    Oguri T, Isobe T, Mitsuta K, Masuda K, Daga H, Ishikawa N, Fujitaka K, Miyazaki M, Kohno N.
    Anticancer Res; 2001 Nov; 21(6A):3933-6. PubMed ID: 11911273
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. [Usefulness of intraperitoneal carboplatin administration-- pharmacokinetic analysis].
    Ito K, Itani Y, Furuki K, Tamori N, Noda T, Adachi S, Hirano Y, Kato Y, Kiyozuka Y.
    Nihon Sanka Fujinka Gakkai Zasshi; 1992 Sep; 44(9):1180-6. PubMed ID: 1453047
    [Abstract] [Full Text] [Related]

  • 18. Intraperitoneal carboplatin with or without interferon-alpha in advanced ovarian cancer patients with minimal residual disease at second look: a prospective randomized trial of 111 patients. G.O.N.O. Gruppo Oncologic Nord Ovest.
    Bruzzone M, Rubagotti A, Gadducci A, Catsafados E, Foglia G, Brunetti I, Giannessi PG, Carnino F, Iskra L, Rosso R, Martoni A, Pannuti F, De Lisi V, Maltoni R, Ridolfi R, Mammoliti S, Gallo L, Boccardo F, Ragni N, Conte PF.
    Gynecol Oncol; 1997 Jun; 65(3):499-505. PubMed ID: 9190982
    [Abstract] [Full Text] [Related]

  • 19. Comparative pharmacokinetics of oxaliplatin (L-OHP) and carboplatin (CBDCA) in mice with reference to circadian dosing time.
    Boughattas NA, Hecquet B, Fournier C, Bruguerolle B, Trabelsi H, Bouzouita K, Omrane B, Lévi F.
    Biopharm Drug Dispos; 1994 Dec; 15(9):761-73. PubMed ID: 7888604
    [Abstract] [Full Text] [Related]

  • 20. Response of peritoneal solid tumours after intraperitoneal chemohyperthermia treatment with cisplatin or carboplatin.
    Los G, van Vugt MJ, Pinedo HM.
    Br J Cancer; 1994 Feb; 69(2):235-41. PubMed ID: 8297720
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.